Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 98422T100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Point72 Asset Management, L.P.
13G/A
Amendment 2
|
0% |
5/15/2026
Event 3/31/2026
|
|
| Point72 Asset Management, L.P. | 0% | ||
| Point72 Capital Advisors, Inc. | 0% | ||
| Steven A. Cohen | 0% | ||
|
Sirenia Capital Management LP
13G
|
9.9% |
5/15/2026
Event 3/31/2026
|
|
| Sirenia Capital Management LP | 9.9% | ||
| Alex Silverstein | 9.9% | ||
|
Bain Capital Life Sciences Fund II, L.P.
13G/A
Amendment 3
|
8.5% |
2/17/2026
Event 12/31/2025
|
|
| Bain Capital Life Sciences Fund II, L.P. | 1.3% | ||
| BCIP Life Sciences Associates, LP | 0.2% | ||
| BCLS II Equity Opportunities, LP | 8.5% | ||
| BCLS II Investco, LP | 0% | ||
|
StemPoint Capital LP
13G/A
Amendment 1
|
8.4% |
2/17/2026
Event 12/31/2025
|
|
| StemPoint Capital LP | 8.4% | ||
| StemPoint Capital Management GP LLC | 8.4% | ||
| Michelle Ross | 8.4% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 2
|
6.7% |
2/13/2026
Event 12/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 6.7% | ||
| FHMLSP, L.P. | 6.7% | ||
| FHMLSP, L.L.C. | 6.7% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.6% | ||
| FHMLS XI, L.P. | 0.6% | ||
| FHMLS XI, L.L.C. | 0.6% | ||
| Frazier Life Sciences XII, L.P. | 1.0% | ||
| FHMLS XII, L.P. | 1.0% | ||
| FHMLS XII, L.L.C. | 1.0% | ||
| James N. Topper | 0.2% | ||
| Patrick J. Heron | 0.2% | ||
| Gilead Sciences, Inc. 13G/A Amendment 3 | 19.9% |
2/12/2026
Event 12/31/2025
|
|
|
Coastlands Capital LP
13G
|
10.0% |
12/11/2025
Event 12/4/2025
|
|
| Coastlands Capital LP | 10.0% | ||
| Coastlands Capital Partners LP | 10.0% | ||
| Coastlands Capital GP LLC | 10.0% | ||
| Coastlands Capital LLC | 10.0% | ||
| Matthew D. Perry | 10.0% | ||
|
StemPoint Capital LP
13G
|
7.2% |
11/14/2025
Event 9/30/2025
|
|
| StemPoint Capital LP | 7.2% | ||
| StemPoint Capital Management GP LLC | 7.2% | ||
| Michelle Ross | 7.2% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
9.9% |
11/14/2025
Event 9/30/2025
|
|
| Point72 Asset Management, L.P. | 9.9% | ||
| Point72 Capital Advisors, Inc. | 9.9% | ||
| Steven A. Cohen | 9.9% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 9.9% | ||
| FHMLSP, L.P. | 9.9% | ||
| FHMLSP, L.L.C. | 9.9% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 4.4% | ||
| FHMLSP Overage, L.P. | 4.4% | ||
| FHMLSP Overage, L.L.C. | 4.4% | ||
| Frazier Life Sciences X, L.P. | 0.6% | ||
| FHMLS X, L.P. | 0.6% | ||
| FHMLS X, L.L.C. | 0.6% | ||
| Frazier Life Sciences XI, L.P. | 1.7% | ||
| FHMLS XI, L.P. | 1.7% | ||
| FHMLS XI, L.L.C. | 1.7% | ||
| Frazier Life Sciences XII, L.P. | 2.9% | ||
| FHMLS XII, L.P. | 2.9% | ||
| FHMLS XII, L.L.C. | 2.9% | ||
| James N. Topper | 0.6% | ||
| Patrick J. Heron | 0.6% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
| Gilead Sciences, Inc. 13G/A Amendment 2 | 19.9% |
8/14/2025
Event 6/30/2025
|
|
|
Point72 Asset Management, L.P.
13G
|
7.2% |
6/17/2025
Event 6/5/2025
|
|
| Point72 Asset Management, L.P. | 7.2% | ||
| Point72 Capital Advisors, Inc. | 7.2% | ||
| Steven A. Cohen | 7.2% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
9.9% |
6/12/2025
Event 6/5/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 6.3% | ||
| FHMLSP, L.P. | 6.3% | ||
| FHMLSP, L.L.C. | 6.3% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.0% | ||
| FHMLSP Overage, L.P. | 2.0% | ||
| FHMLSP Overage, L.L.C. | 2.0% | ||
| Frazier Life Sciences X, L.P. | 0.3% | ||
| FHMLS X, L.P. | 0.3% | ||
| FHMLS X, L.L.C. | 0.3% | ||
| Frazier Life Sciences XI, L.P. | 0.7% | ||
| FHMLS XI, L.P. | 0.7% | ||
| FHMLS XI, L.L.C. | 0.7% | ||
| Frazier Life Sciences XII, L.P. | 1.3% | ||
| FHMLS XII, L.P. | 1.3% | ||
| FHMLS XII, L.L.C. | 1.3% | ||
| James N. Topper | 9.9% | ||
| Patrick J. Heron | 9.9% | ||
| Albert Cha | 8.1% | ||
| James Brush | 8.1% | ||
| Daniel Estes | 2.0% | ||
|
Rock Springs Capital Management LP
13G/A
Amendment 3
|
0% |
5/15/2025
Event 3/31/2025
|
|
| Rock Springs Capital Management LP | 0% | ||
| Rock Springs Capital LLC | 0% | ||
| Rock Springs Capital Master Fund LP | 0% | ||
| Mark Bussard | 0% | ||
| Kris Jenner | 0% | ||
| AbbVie Inc. 13G | 9.0% |
2/18/2025
Event 2/11/2025
|
|
| Gilead Sciences, Inc. 13G/A Amendment 1 | 19.9% |
12/19/2024
Event 12/18/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 1 | 650 k | $6.23 M |
| 2026 Q1 | 1 | 650 k | $5.47 M |
| 2025 Q4 | 37 | 39.7 M | $25.4 M |
| 2025 Q3 | 36 | 22.1 M | $18.6 M |
| 2025 Q2 | 36 | 23.8 M | $16.2 M |
| 2025 Q1 | 36 | 22.5 M | $16.3 M |
| 2024 Q4 | 36 | 25.9 M | $24.7 M |
| 2024 Q3 | 35 | 16.0 M | $12.6 M |
| 2024 Q2 | 35 | 15.6 M | $14.8 M |
| 2024 Q1 | 35 | 12.9 M | $14.0 M |
| 2023 Q4 | 37 | 16.6 M | $9.11 M |
| 2023 Q3 | 32 | 15.9 M | $33.5 M |
| 2023 Q2 | 33 | 16.0 M | $41.9 M |
| 2023 Q1 | 33 | 16.1 M | $51.0 M |
| 2022 Q4 | 30 | 15.9 M | $42.9 M |
| 2022 Q3 | 30 | 16.6 M | $48.3 M |
| 2022 Q2 | 34 | 17.9 M | $52.2 M |
| 2022 Q1 | 42 | 18.8 M | $133 M |
| 2021 Q4 | 43 | 19.0 M | $303 M |